Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: Analysis of 3 randomized trials versus placebo

Lipids in Health and Disease

Volumn 15, Issue 1, 2016, Pages

  Toth, Peter P ^a,b,c   Hamon, Sara C ^d   Jones, Steven R ^c   Martin, Seth S ^c   Joshi, Parag H ^c,e   Kulkarni, Krishnaji R ^f   Banerjee, Poulabi ^d   Hanotin, Corinne ^g   Roth, Eli M ^h   McKenney, James M ⁱ  

^a CGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d REGENERON PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f Atherotech   (United States)

^g SANOFI   (France)

^h Sterling Research Group   (United States)

ⁱ VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Alirocumab; Hypercholesterolaemia; Lipoprotein subfraction; PCSK9; VAP

Indexed keywords

ALIROCUMAB; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN 1; LOW DENSITY LIPOPROTEIN 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; MONOCLONAL ANTIBODY; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG MECHANISM; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTIBODIES, MONOCLONAL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES;

EID: 84957644236     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-016-0197-4     Document Type: Article

References (32)

1. Rader DJ, Hoeg JM, Brewer Jr. HB. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994;120:1012-25.
2. Reiner Z, Catapano AL, De BG, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818.
3. Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: A reappraisal. J Clin Endocrinol Metab. 2003;88:4525-32.
4. Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239:483-95.
5. Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21:305-11.
6. Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5:338-67.
7. Jong MC, Rensen PC, Dahlmans VE, van der Boom H, van Berkel TJ, Havekes LM. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-Type and apoE knockout mice. J Lipid Res. 2001;42:1578-85.
8. Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism. 2012;61:906-21.
9. Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013;62:732-9.
10. Kulkarni KR, Garber DW, Marcovina SM, Segrest JP. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res. 1994;35:159-68.
11. Kulkarni KR. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med. 2006;26:787-802.
12. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310:2061-8.
13. Seidah NG, Awan Z, Chretien M, Mbikay M. PCSK9: A key modulator of cardiovascular health. Circ Res. 2014;114:1022-36.
14. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-53.
15. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891-900.
16. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce lowdensity lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet. 2012;380:29-36.
17. Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol. 2014;176:55-61.
18. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: The ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186-94.
19. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-99.
20. Bays H, Conard S, Leiter LA, Bird S, Jensen E, Hanson ME, et al. Are posttreatment low-density lipoprotein subclass pattern analyses potentially misleading? Lipids Health Dis. 2010;9:136.
21. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.
22. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet. 2001;358:2026-33.
23. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52.
24. Bays HE, Jones PH, Brown WV, Jacobson TA. National Lipid Association Annual Summary of Clinical Lipidology 2015. J Clin Lipidol. 2014;8:S1-36.
25. Jones C, Garuti R, Michaely P, Li WP, Maeda N, Cohen JC, et al. Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia. J Clin Invest. 2007;117:165-74.
26. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008;88:887-918.
27. MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest. 2007;117:153-64.
28. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427-36.
29. Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34:1826-33.
30. O'Keefe Jr. JH, Captain BK, Jones PG, Harris WS. Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern. Prev Cardiol. 2004;7:154-60.
31. Martin SS, Blaha MJ, Toth PP, Joshi PH, McEvoy JW, Ahmed HM, et al. Very large database of lipids: Rationale and design. Clin Cardiol. 2013;36:641-8.
32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.